This article presents demographic and detailed clinical data from 159 patients with Parkinson's disease or atypical Parkinsonian syndromes treated in the Parkinson's disease multimodal complex treatment (PD-MCT) from 01.01.2019 until 31.12.2019 at the Department of Neurology of the University Hospital Jena, Germany. At baseline, the following variables were collected: age, sex, diagnosis, phenotype, disease duration, Hoehn and Yahr stage, Movement Disorder Society sponsored revision of the unified Parkinson's disease rating scale (MDS-UPDRS) part I-IV, levodopa equivalent daily dose (LEDD), Tinetti test, nonmotor symptoms questionnaire (NMSQ), Montreal Cognitive Assessment (MoCA), measures of depressive symptoms using the Hospital Anxiety and Depression Scale (HADS-D) and the Beck Depression Inventory (BDI-II), health-related quality of life assessed by the Short-Form Health Survey (SF-12), and the treatment duration according to the Operation and Procedure Classification System. To assess the short-term effect of PD-MCT, the MDS-UPDRS III, Tinetti test, and LEDD were collected again at discharge from hospital. One month after discharge, a first follow-up was conducted and patients rated their general condition. One year after discharge, a second follow-up was conducted and the SF-12 was collected. The dataset allows determination of the effect of PD-MCT and identification of predictors of a beneficial treatment. The dataset can be used by clinicians and academia for further research and as reference. The dataset can also be used in a large range of other topics where demographic and clinical parameters of the PD-MCT are relevant. The data presented herein is associated with the research article "Short- and Long-Term Effect of Parkinson's Disease Multimodal Complex Treatment" [1] and available on Mendeley Data [2].
Keywords: Depression; Health services research; Multidisciplinary care; Parkinson's disease; Quality of life.
© 2022 The Author(s). Published by Elsevier Inc.